Loading...
XNAS
HOLX
Market cap14bUSD
Jul 22, Last price  
65.37USD
1D
2.64%
1Q
12.42%
Jan 2017
62.94%
Name

Hologic Inc

Chart & Performance

D1W1MN
P/E
18.45
P/S
3.61
EPS
3.54
Div Yield, %
—
Shrs. gr., 5y
-2.49%
Rev. gr., 5y
3.66%
Revenues
4.03b
0.00%
287,684,000462,680,000738,368,0001,674,499,0001,637,134,0001,679,552,0001,789,349,0002,002,652,0002,492,279,0002,530,700,0002,705,000,0002,832,700,0003,058,800,0003,217,900,0003,367,300,0003,776,400,0005,632,300,0004,862,800,0004,030,400,0004,030,300,000
Net income
790m
+73.14%
28,256,00027,423,00094,578,000-385,617,000-2,176,237,000-62,813,000157,150,000-73,634,000-1,172,838,00017,300,000131,600,000330,800,000755,500,000-111,300,000-40,200,0001,115,200,0001,871,500,0001,302,000,000456,000,000789,500,000
CFO
1.29b
+22.26%
44,373,00031,124,000153,250,000364,596,000546,365,000456,712,000456,024,000370,222,000493,822,000508,400,000786,100,000787,200,0008,300,000732,900,000649,500,000896,600,0002,330,400,0002,125,700,0001,051,200,0001,285,200,000
Earnings
Jul 28, 2025

Profile

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
URL
https://www.hologic.com/
IPO date
Mar 01, 1990
Employees
6,478
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑092015‑09
Income
Revenues
4,030,300
0.00%
4,030,400
-17.12%
4,862,800
-13.66%
Cost of revenue
3,070,100
3,240,800
3,186,800
Unusual Expense (Income)
NOPBT
960,200
789,600
1,676,000
NOPBT Margin
23.82%
19.59%
34.47%
Operating Taxes
75,600
220,100
286,200
Tax Rate
7.87%
27.87%
17.08%
NOPAT
884,600
569,500
1,389,800
Net income
789,500
73.14%
456,000
-64.98%
1,302,000
-30.43%
Dividends
Dividend yield
Proceeds from repurchase of equity
(797,300)
(431,800)
(490,800)
BB yield
4.15%
2.50%
3.07%
Debt
Debt current
64,800
310,500
15,000
Long-term debt
2,716,600
2,612,000
2,906,600
Deferred revenue
13,800
13,800
9,400
Other long-term liabilities
10,600
13,200
348,700
Net debt
351,400
220,200
576,600
Cash flow
Cash from operating activities
1,285,200
1,051,200
2,125,700
CAPEX
(72,400)
(150,200)
(127,200)
Cash from investing activities
(781,000)
(152,100)
(206,300)
Cash from financing activities
(1,108,600)
(483,200)
(756,000)
FCF
873,900
537,100
1,857,700
Balance
Cash
2,333,600
2,722,500
2,339,500
Long term investments
96,400
(20,200)
5,500
Excess cash
2,228,485
2,500,780
2,101,860
Stockholders' equity
(111,500)
1,911,700
1,365,100
Invested Capital
7,923,900
6,310,600
6,648,400
ROIC
12.43%
8.79%
19.87%
ROCE
11.73%
9.58%
20.68%
EV
Common stock shares outstanding
237,553
248,831
253,845
Price
80.82
16.46%
69.40
10.19%
62.98
-17.65%
Market cap
19,199,033
11.18%
17,268,871
8.02%
15,987,158
-19.51%
EV
19,550,433
17,489,071
16,563,758
EBITDA
1,269,200
1,113,000
2,106,100
EV/EBITDA
15.40
15.71
7.86
Interest
122,100
111,100
95,100
Interest/NOPBT
12.72%
14.07%
5.67%